The agency first approved Avycaz in 2015 to treat adults with intra-abdominal infections in combination with metronidazole. In 2016, the FDA OK’d the antibiotic to treat complicated urinary tract infections and kidney infections.
Clinicians may now use Avycaz to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, both caused by drug-resistant bacteria.
More articles on supply chain:
10 most-read supply chain stories in January
FDA approves record number of personalized medicines in 2017: 4 things to know
FDA approves treatment for C. diff-associated diarrhea: 3 things to know
